The demo accomplished both its Main endpoints, with semaglutide 2.4 mg demonstrating statistically significant and excellent advancements in liver fibrosis without having worsening of steatohepatitis, and resolution of steatohepatitis without having worsening of liver fibrosis in those with MASH in comparison with placebo.1Connect with your medical